|
In individuals with episodic migraine, we recommend eptinezumab, erenumab, fremanezumab and galcanezumab as preventive treatment Quality of evidence: moderate to high Strength of the recommendation: strong |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.